< Back to Portfolio

Basilard Biotech

Revolutionizing cell and gene therapy.

  • company-website-icon
  • company-linkedin-icon

About

Basilard Biotech is a Southern-California-based company poised to lead a revolution in the engineering of cell-based therapies in Cell and Gene Therapy (CGT). In 2019, the company launched a disruptive gene delivery technology platform called Celletto. This novel approach to nanomechanical gene delivery has the potential to disrupt the current limitations of viral and non-viral gene delivery—a breakthrough that could facilitate better scalability and more cost-effective production of cell and gene therapies.

  • Location: Temecula, CA
  • Paladin Initial Investment Date: January 2021

Portfolio Stats

Over 65 Companies

Paladin has invested in over 65 portfolio companies since 2001.

4 Continents

Paladin has invested in companies in North America, Australia, Europe, and South America.

Over $1 billion

Paladin manages over $1 billion of committed capital across multiple funds and investment vehicles.